Cue Biopharma (CUE)

• Market cap: $120M
• 1 day: 6.47%
• 5 days: 5.06%
• 1 month: 33.12%
• 3 months: 258.89%
• 6 months: 177.39%
• Year to date: 181.23%
• 1 year: 44.69%
• 5 years: -92.45%
• 10 years: -91.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Employees: 29